Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
Dazhi LiuMichael A WeintraubChristine GarciaMarcus D GoncalvesAnn Elizabeth SiskAlissa CasasJames J HardingStephen HarnicarAlexander DrilonKomal JhaveriJames H FloryPublished in: Cancer medicine (2022)
Hyperglycemia is one of the major on-target side effects of PI3K and AKT inhibitors. It is manageable with antidiabetic medications, treatment interruption and/or dose modification. We summarize pharmacological interventions that may be considered for PI3K/AKT inhibitor induced hyperglycemia. SGLT2-inhibitor may be a particularly effective second-line option after metformin but there is a low risk of euglycemic DKA, which can be deadly. To our knowledge, our report is the largest study of hyperglycemia in patients receiving PI3K/AKT inhibitors.